10-Q Filing

MERCK & CO., INC. CIK: 310158 Q3 2024

Filing Information

Form Type	10-Q
Accession Number	`0001628280-24-045689`
Period End Date	20240930
Filing Date	20241106
Fiscal Year	2024
Fiscal Period	Q3
XBRL Instance	mrk-20240930_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 160 Income Statement 112 Cash Flow Statement 168 Comprehensive Income 48

Balance Sheet 160 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$79.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$79.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$88.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$88.00M	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.35B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$3.35B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$4.00B	USD	Point-in-time
Inventories classified in Other assets	`InventoryNoncurrent`	$4.00B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.27B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.27B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$19.07B	USD	Point-in-time
Accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$19.07B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.84B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.84B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$14.59B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$14.59B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	-	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	-	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$252.00M	USD	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$252.00M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $79 in 2024 and $88 in 2023)	`AccountsReceivableNetCurrent`	$10.35B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $79 in 2024 and $88 in 2023)	`AccountsReceivableNetCurrent`	$10.35B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $79 in 2024 and $88 in 2023)	`AccountsReceivableNetCurrent`	$11.38B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $79 in 2024 and $88 in 2023)	`AccountsReceivableNetCurrent`	$11.38B	USD	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Common stock, authorized (shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Inventories (excludes inventories of $3,995 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)	`InventoryNet`	$6.24B	USD	Point-in-time
Inventories (excludes inventories of $3,995 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)	`InventoryNet`	$6.24B	USD	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Inventories (excludes inventories of $3,995 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)	`InventoryNet`	$6.36B	USD	Point-in-time
Inventories (excludes inventories of $3,995 in 2024 and $3,348 in 2023 classified in Other assets - see Note 6)	`InventoryNet`	$6.36B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.05B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.05B	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$8.14B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$8.14B	USD	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.05B	shares	Point-in-time
Treasury stock (in shares)	`TreasuryStockCommonShares`	1.05B	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$8.37B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$8.37B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$32.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$32.17B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$40.36B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$40.36B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$252.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$252.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$575.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$575.00M	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $19,072 in 2024 and $18,266 in 2023	`PropertyPlantAndEquipmentNet`	$23.45B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $19,072 in 2024 and $18,266 in 2023	`PropertyPlantAndEquipmentNet`	$23.45B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $19,072 in 2024 and $18,266 in 2023	`PropertyPlantAndEquipmentNet`	$23.05B	USD	Point-in-time
Property, Plant and Equipment, at cost, net of accumulated depreciation of $19,072 in 2024 and $18,266 in 2023	`PropertyPlantAndEquipmentNet`	$23.05B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Goodwill	`Goodwill`	$21.20B	USD	Point-in-time
Goodwill	`Goodwill`	$21.70B	USD	Point-in-time
Goodwill	`Goodwill`	$21.70B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$18.01B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$18.01B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$17.01B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$17.01B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$14.44B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$14.44B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$12.00B	USD	Point-in-time
Other Assets	`OtherAssetsNoncurrent`	$12.00B	USD	Point-in-time
Total Assets	`Assets`	$106.67B	USD	Point-in-time
Total Assets	`Assets`	$106.67B	USD	Point-in-time
Total Assets	`Assets`	$117.53B	USD	Point-in-time
Total Assets	`Assets`	$117.53B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$3.15B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$3.15B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.37B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$1.37B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.59B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.59B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.92B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.92B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$16.54B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$16.54B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$15.77B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$15.77B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$4.33B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$4.33B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.65B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$2.65B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.98B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.98B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.99B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.99B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$29.59B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$29.59B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.69B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$25.69B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$33.68B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$33.68B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$34.98B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$34.98B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$864.00M	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$864.00M	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$871.00M	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$871.00M	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.79B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$8.79B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$7.54B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$7.54B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2024 and 2023	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.53B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.53B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.51B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$44.51B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$61.38B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$61.38B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$53.90B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$53.90B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.37B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.37B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.16B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-5.16B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$95.03B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$95.03B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$102.33B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$102.33B	USD	Point-in-time
Less treasury stock, at cost: 1,045,073,377 shares in 2024 and 1,045,470,249 shares in 2023	`TreasuryStockCommonValue`	$57.45B	USD	Point-in-time
Less treasury stock, at cost: 1,045,073,377 shares in 2024 and 1,045,470,249 shares in 2023	`TreasuryStockCommonValue`	$57.45B	USD	Point-in-time
Less treasury stock, at cost: 1,045,073,377 shares in 2024 and 1,045,470,249 shares in 2023	`TreasuryStockCommonValue`	$57.83B	USD	Point-in-time
Less treasury stock, at cost: 1,045,073,377 shares in 2024 and 1,045,470,249 shares in 2023	`TreasuryStockCommonValue`	$57.83B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$37.58B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$37.58B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$44.50B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$44.50B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$54.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$54.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$58.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$58.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$43.65B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$43.65B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$37.63B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$37.63B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$46.06B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$41.30B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$41.30B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.74B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$38.74B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$44.56B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$44.56B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$106.67B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$106.67B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$117.53B	USD	Point-in-time
Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$117.53B	USD	Point-in-time

Income Statement 112 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$15.96B	USD	1 Quarter
Sales	`Revenues`	$15.96B	USD	1 Quarter
Sales	`Revenues`	$16.66B	USD	1 Quarter
Sales	`Revenues`	$16.66B	USD	1 Quarter
Sales	`Revenues`	$45.48B	USD	3 Qtrs
Sales	`Revenues`	$45.48B	USD	3 Qtrs
Sales	`Revenues`	$48.54B	USD	3 Qtrs
Sales	`Revenues`	$48.54B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$11.37B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$11.37B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$4.08B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$4.08B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$4.26B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$4.26B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$12.21B	USD	3 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$12.21B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.73B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.73B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.52B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$2.52B	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.95B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.95B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.70B	USD	3 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$7.70B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$3.31B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$3.31B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.86B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$5.86B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$13.35B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$13.35B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$20.90B	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$20.90B	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$344.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$344.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$56.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$56.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$258.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$258.00M	USD	3 Qtrs
Restructuring costs	`RestructuringCharges`	$126.00M	USD	1 Quarter
Restructuring costs	`RestructuringCharges`	$126.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$162.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$162.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$151.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$151.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-126.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-126.00M	USD	1 Quarter
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-388.00M	USD	3 Qtrs
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-388.00M	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.34B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$10.34B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$12.57B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$12.57B	USD	1 Quarter
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$41.55B	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$41.55B	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$32.78B	USD	3 Qtrs
Total Costs, Expenses and Other	`CostsExpensesAndOther`	$32.78B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$15.77B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$15.77B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.09B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$4.09B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.62B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$5.62B	USD	1 Quarter
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.94B	USD	3 Qtrs
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$3.94B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$2.33B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$2.33B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$870.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$870.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$2.38B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$2.38B	USD	3 Qtrs
Taxes on Income	`IncomeTaxExpenseBenefit`	$929.00M	USD	1 Quarter
Taxes on Income	`IncomeTaxExpenseBenefit`	$929.00M	USD	1 Quarter
Net Income	`ProfitLoss`	$4.75B	USD	1 Quarter
Net Income	`ProfitLoss`	$4.75B	USD	1 Quarter
Net Income	`ProfitLoss`	$3.16B	USD	1 Quarter
Net Income	`ProfitLoss`	$3.16B	USD	1 Quarter
Net Income	`ProfitLoss`	$1.60B	USD	3 Qtrs
Net Income	`ProfitLoss`	$1.60B	USD	3 Qtrs
Net Income	`ProfitLoss`	$13.39B	USD	3 Qtrs
Net Income	`ProfitLoss`	$13.39B	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$12.00M	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$12.00M	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$15.00M	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$15.00M	USD	3 Qtrs
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$5.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$4.00M	USD	1 Quarter
Less: Net Income Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$4.00M	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.75B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.75B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.16B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.16B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$13.37B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$13.37B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.59B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.59B	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$5.28	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$5.28	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.87	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.87	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.25	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$1.25	USD	1 Quarter
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$0.63	USD	3 Qtrs
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$0.63	USD	3 Qtrs
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.24	USD	1 Quarter
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.24	USD	1 Quarter
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.86	USD	1 Quarter
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$1.86	USD	1 Quarter
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$0.62	USD	3 Qtrs
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$0.62	USD	3 Qtrs
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$5.26	USD	3 Qtrs
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$5.26	USD	3 Qtrs

Cash Flow Statement 168 line items

Line Item	Tag	Value	Unit	Period
Restricted cash	`RestrictedCashAndCashEquivalents`	$68.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$68.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$64.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$64.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$79.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$95.00M	USD	Point-in-time
Restricted cash	`RestrictedCashAndCashEquivalents`	$95.00M	USD	Point-in-time
Net income	`ProfitLoss`	$4.75B	USD	1 Quarter
Net income	`ProfitLoss`	$4.75B	USD	1 Quarter
Net income	`ProfitLoss`	$3.16B	USD	1 Quarter
Net income	`ProfitLoss`	$3.16B	USD	1 Quarter
Net income	`ProfitLoss`	$1.60B	USD	3 Qtrs
Net income	`ProfitLoss`	$1.60B	USD	3 Qtrs
Net income	`ProfitLoss`	$13.39B	USD	3 Qtrs
Net income	`ProfitLoss`	$13.39B	USD	3 Qtrs
Amortization	`AdjustmentForAmortization`	$1.58B	USD	3 Qtrs
Amortization	`AdjustmentForAmortization`	$1.58B	USD	3 Qtrs
Amortization	`AdjustmentForAmortization`	$1.72B	USD	3 Qtrs
Amortization	`AdjustmentForAmortization`	$1.72B	USD	3 Qtrs
Depreciation	`Depreciation`	$1.33B	USD	3 Qtrs
Depreciation	`Depreciation`	$1.33B	USD	3 Qtrs
Depreciation	`Depreciation`	$1.58B	USD	3 Qtrs
Depreciation	`Depreciation`	$1.58B	USD	3 Qtrs
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-31.00M	USD	1 Quarter
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-31.00M	USD	1 Quarter
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$169.00M	USD	3 Qtrs
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$169.00M	USD	3 Qtrs
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$240.00M	USD	3 Qtrs
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$240.00M	USD	3 Qtrs
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-33.00M	USD	1 Quarter
Income from investments in equity securities, net	`EquitySecuritiesFvNiGainLoss`	$-33.00M	USD	1 Quarter
Charge for the acquisition of Eyebiotech Limited	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionFour`	-	USD	3 Qtrs
Charge for the acquisition of Eyebiotech Limited	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionFour`	-	USD	3 Qtrs
Charge for the acquisition of Eyebiotech Limited	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionFour`	$1.35B	USD	3 Qtrs
Charge for the acquisition of Eyebiotech Limited	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionFour`	$1.35B	USD	3 Qtrs
Charge for the acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionFive`	-	USD	3 Qtrs
Charge for the acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionFive`	-	USD	3 Qtrs
Charge for the acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionFive`	$750.00M	USD	3 Qtrs
Charge for the acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionFive`	$750.00M	USD	3 Qtrs
Charge for the acquisition of Harpoon Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionTwo`	-	USD	3 Qtrs
Charge for the acquisition of Harpoon Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionTwo`	-	USD	3 Qtrs
Charge for the acquisition of Harpoon Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionTwo`	$656.00M	USD	3 Qtrs
Charge for the acquisition of Harpoon Therapeutics, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionTwo`	$656.00M	USD	3 Qtrs
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionThree`	$10.22B	USD	3 Qtrs
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionThree`	$10.22B	USD	3 Qtrs
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionThree`	-	USD	3 Qtrs
Charge for the acquisition of Prometheus Biosciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationOrJointVentureFormationWriteoffAssetAcquisitionThree`	-	USD	3 Qtrs
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.19B	USD	3 Qtrs
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	$1.19B	USD	3 Qtrs
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	3 Qtrs
Charge for the acquisition of Imago BioSciences, Inc.	`ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff`	-	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-968.00M	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-968.00M	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-633.00M	USD	3 Qtrs
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-633.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$478.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$478.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$574.00M	USD	3 Qtrs
Share-based compensation	`ShareBasedCompensation`	$574.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$81.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$81.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$-611.00M	USD	3 Qtrs
Other	`OtherNoncashIncomeExpense`	$-611.00M	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.81B	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.81B	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.35B	USD	3 Qtrs
Net changes in assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$2.35B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$18.02B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$18.02B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$12.76B	USD	3 Qtrs
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$12.76B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.44B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.44B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.87B	USD	3 Qtrs
Capital expenditures	`PaymentsToAcquirePropertyPlantAndEquipment`	$2.87B	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$704.00M	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$704.00M	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$64.00M	USD	3 Qtrs
Purchases of securities and other investments	`PaymentsToAcquireInvestments`	$64.00M	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$1.49B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$1.49B	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$370.00M	USD	3 Qtrs
Proceeds from sales of securities and other investments	`ProceedsFromSaleAndMaturityOfOtherInvestments`	$370.00M	USD	3 Qtrs
Acquisition of Eyebiotech Limited, net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Eyebiotech Limited, net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Eyebiotech Limited, net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	$1.34B	USD	3 Qtrs
Acquisition of Eyebiotech Limited, net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	$1.34B	USD	3 Qtrs
Acquisition of Elanco Animal Health Incorporated aqua business	`PaymentsToAcquireBusinessFour`	-	USD	3 Qtrs
Acquisition of Elanco Animal Health Incorporated aqua business	`PaymentsToAcquireBusinessFour`	-	USD	3 Qtrs
Acquisition of Elanco Animal Health Incorporated aqua business	`PaymentsToAcquireBusinessFour`	$1.30B	USD	3 Qtrs
Acquisition of Elanco Animal Health Incorporated aqua business	`PaymentsToAcquireBusinessFour`	$1.30B	USD	3 Qtrs
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$746.00M	USD	3 Qtrs
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$746.00M	USD	3 Qtrs
Acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical	`PaymentsToAcquireGlobalRights`	-	USD	3 Qtrs
Acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical	`PaymentsToAcquireGlobalRights`	-	USD	3 Qtrs
Acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical	`PaymentsToAcquireGlobalRights`	$700.00M	USD	3 Qtrs
Acquisition of MK-1045 (formerly CN201) from Curon Pharmaceutical	`PaymentsToAcquireGlobalRights`	$700.00M	USD	3 Qtrs
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	$10.71B	USD	3 Qtrs
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	$10.71B	USD	3 Qtrs
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	3 Qtrs
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.33B	USD	3 Qtrs
Acquisition of Imago BioSciences, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$1.33B	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$70.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$70.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$15.00M	USD	3 Qtrs
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$15.00M	USD	3 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-6.29B	USD	3 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-6.29B	USD	3 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-14.14B	USD	3 Qtrs
Net Cash Used in Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-14.14B	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfDebt`	$5.94B	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfDebt`	$5.94B	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfDebt`	$3.60B	USD	3 Qtrs
Proceeds from issuance of debt	`ProceedsFromIssuanceOfDebt`	$3.60B	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$751.00M	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$751.00M	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.75B	USD	3 Qtrs
Payments on debt	`RepaymentsOfLongTermDebt`	$1.75B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.59B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.59B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.89B	USD	3 Qtrs
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.89B	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$953.00M	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$953.00M	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$817.00M	USD	3 Qtrs
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$817.00M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$119.00M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$119.00M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$165.00M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$165.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-330.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-330.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-325.00M	USD	3 Qtrs
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-325.00M	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.56B	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.56B	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-4.02B	USD	3 Qtrs
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-4.02B	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-163.00M	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-163.00M	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$74.00M	USD	3 Qtrs
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$74.00M	USD	3 Qtrs
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$7.78B	USD	3 Qtrs
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$7.78B	USD	3 Qtrs
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-4.10B	USD	3 Qtrs
Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-4.10B	USD	3 Qtrs
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.69B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.69B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.67B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $68 and $79 at January 1, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.67B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $95 and $64 at September 30, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $95 and $64 at September 30, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$12.77B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $95 and $64 at September 30, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.69B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $95 and $64 at September 30, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$14.69B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $95 and $64 at September 30, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $95 and $64 at September 30, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.91B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $95 and $64 at September 30, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.67B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $95 and $64 at September 30, 2024 and 2023, respectively, included in Other current assets)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.67B	USD	Point-in-time

Comprehensive Income 48 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.75B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$4.75B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.16B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$3.16B	USD	1 Quarter
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$13.37B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$13.37B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.59B	USD	3 Qtrs
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$1.59B	USD	3 Qtrs
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-99.00M	USD	3 Qtrs
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-99.00M	USD	3 Qtrs
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$171.00M	USD	3 Qtrs
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$171.00M	USD	3 Qtrs
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-296.00M	USD	1 Quarter
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-296.00M	USD	1 Quarter
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$159.00M	USD	1 Quarter
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$159.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$13.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$13.00M	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$28.00M	USD	3 Qtrs
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$28.00M	USD	3 Qtrs
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	-	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	-	USD	1 Quarter
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$75.00M	USD	3 Qtrs
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent`	$75.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-83.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-83.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-244.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-244.00M	USD	3 Qtrs
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-175.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-175.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$299.00M	USD	1 Quarter
Cumulative translation adjustment	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$299.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-210.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-210.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-10.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-10.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-16.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-16.00M	USD	1 Quarter
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-148.00M	USD	3 Qtrs
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-148.00M	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.73B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$4.73B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$3.15B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$3.15B	USD	1 Quarter
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$1.44B	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$1.44B	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$13.16B	USD	3 Qtrs
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$13.16B	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.